Janux Therapeutics (JANX) EBT Margin (2021 - 2025)
Historic EBT Margin for Janux Therapeutics (JANX) over the last 5 years, with Q3 2025 value amounting to 243.13%.
- Janux Therapeutics' EBT Margin rose 61484400.0% to 243.13% in Q3 2025 from the same period last year, while for Sep 2025 it was 1018.95%, marking a year-over-year decrease of 5550400.0%. This contributed to the annual value of 651.62% for FY2024, which is 695600.0% up from last year.
- Latest data reveals that Janux Therapeutics reported EBT Margin of 243.13% as of Q3 2025, which was up 61484400.0% from 6391.57% recorded in Q3 2024.
- In the past 5 years, Janux Therapeutics' EBT Margin registered a high of 66.98% during Q2 2024, and its lowest value of 6391.57% during Q3 2024.
- Moreover, its 5-year median value for EBT Margin was 837.06% (2021), whereas its average is 1126.13%.
- Per our database at Business Quant, Janux Therapeutics' EBT Margin plummeted by -59319800bps in 2024 and then surged by 61484400bps in 2025.
- Over the past 5 years, Janux Therapeutics' EBT Margin (Quarter) stood at 830.2% in 2021, then surged by 32bps to 564.67% in 2022, then rose by 15bps to 477.77% in 2023, then plummeted by -1238bps to 6391.57% in 2024, then skyrocketed by 96bps to 243.13% in 2025.
- Its EBT Margin stands at 243.13% for Q3 2025, versus 6391.57% for Q3 2024 and 66.98% for Q2 2024.